CANCER VACCINE TREATMENT BY SYNCHRONOUSLY CULTURING AND IMMUNIZING OF AUTOLOGOUS NK (NATURAL KILLER) CELLS WITH AUTOLOGOUS CANCER CELLS

摘要

Glioblastoma multiforme (GBM) and anaplastic astrocytoma are the most malignant and most common astrocytic brain tumors, with an incidence of 5 / 100,000 and pro-neuronal, neural, classic, mesenchymal types. There is no definitive treatment and the average life expectancy is 45-71 weeks. The recurrence period is around 9-36 weeks, and radical surgical resection, radio-chemotherapy (Temozolamide, 6-12 cycles) is the standard of care, causing minimal functional and structural loss; In case of recurrence, re-surgery and bevacizumab treatment are performed in appropriate cases. The proposed vaccine aims to prevent recurrence and definitive treatment in the treatment of GBM and anaplastic astrocytoma and in the treatment of some Grade 2 astrocytomas. However, this approach can be applied to all human solid cancers.